ClinicalTrials.gg
Active, not recruitingNCT07223983Updated Sep 10, 2026

Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS)

A Phase 1 interventional study of Semaglutide 1.0 mg in Alcohol Use Disorder, Weight Loss and Bariatric Surgery Patients, sponsored by Yale University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Yale University · Phase 1, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies testing semaglutide in Alcoholism — 6 open to participants now, 8 under way, 2 of them phase 3. Semaglutide · Alcoholism.

Enrollment
12th of 12
4 · median 64
Started
2026
with 5 others
Phase 1
2 of 12
1 open now
Registered
9th of 12
by date
Lead sponsor
3 of 12
Yale University

Among the 12 studies testing semaglutide in Alcoholism, this one is the 12th largest by enrollment, is one of 6 that started in 2026, is one of 2 in phase 1, and was the 9th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

6 of the 12 studies testing semaglutide in Alcoholism are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing semaglutide in Alcoholism, or all of them as a file.
02

Study summary

The purpose of this research study is to evaluate the feasibility of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight or obesity.

Read the detailed description

This study aims to evaluate the feasibility and acceptability of treating Alcohol Use Disorder with Semaglutide after metabolic and bariatric surgery in adults with overweight/obesity. This study will also examine changes in alcohol use disorder and weight. It is hypothesized that the treatment will be feasible and acceptable to participants, and result in reductions in alcohol use and weight.

A recently published randomized controlled trial provided preliminary evidence that Semaglutide can reduce some alcohol craving and drinking outcomes; however, this has not been examined in individuals with a history of bariatric surgery who are at increased risk of alcohol misuse and Alcohol Use Disorder.

03

Conditions studied

  • Alcohol Use Disorder
  • Weight Loss
  • Bariatric Surgery Patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated form
  • Stated willingness to comply with all study procedures and availability for the duration of the study (up to 6 months: 3-month treatment plus 3-month follow up)
  • Age 18 and older
  • Have a ≥30 (or BMI ≥27 with a medical comorbidity) and BMI ≤50 kg/m2
  • Have had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy within the past seven years
  • Meet current criteria for Alcohol Use Disorder
  • Be an otherwise healthy subject without uncontrolled medical problems, as determined by the study physician and medical co-investigators
  • Read, comprehend, and write English at a sufficient level to complete study-related materials
  • For females of : use of highly effective and agreement to use such a method during study participation

Exclusion criteria

Exclusion Criteria:

  • Any of the following: myocardial infarction, stroke, hospitalization for unstable angina, or within the past 60 days prior to screening
  • History or presence of chronic or recurrent pancreatitis
  • History of malignant neoplasms within the past 5 years prior to screening
  • Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2
  • Is currently using other medications for weight loss or other GLP-1 receptor agonists
  • Has a history of allergy or sensitivity to Semaglutide
  • Has a co-existing psychiatric condition that requires hospitalization or more intensive treatment (such as bipolar mood disorders, psychotic illnesses, or severe depression)
  • Has untreated hypertension with a seated systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg, or heart rate > 100 beats/minute
  • Has current uncontrolled hypertension
  • Has current uncontrolled Type I or Type II diabetes mellitus
  • Has untreated hypothyroidism with a TSH > 1.5 times the for the test laboratory with repeat value that also exceeds this limit
  • Has active gallbladder disease
  • Has a history of severe renal, hepatic, neurological, chronic pulmonary disease, or any other unstable medical disorder
  • Has a recent history of substance use disorder (with the exception of cannabis or tobacco use disorder) within the past 12 months
  • Is currently engaging in other treatment for Alcohol Use Disorder or making intentional efforts to quit alcohol use
  • Is currently participating in another clinical study in which the subject is or will be exposed to an or a non-investigational drug or device
  • Is breast-feeding, pregnant, or not using a reliable form of
  • Reports active suicidal or homicidal ideation
  • Any disorder, unwillingness or inability, not covered by any of the other exclusion criteria which, in the investigator's opinion, might have jeopardized the participant's safety or compliance with the protocol
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Semaglutide

    Participants randomized to Semaglutide will be initiated on a 0.25 mg dose (injection) once weekly for 4 weeks (first month) with an escalation to 0.5 mg for the second month, and 1.0 mg in the final month. Participants will be on Semaglutide for three months total.

    Drug: Semaglutide 1.0 mg

  • No intervention
    Wait-list control

    Participants randomized to wait-list control will be followed for three months but no treatment will be administered. At the conclusion of the study, participants in the wait list control group will be offered a three-month behavioral intervention to treat Alcohol Use Disorder, although this is not required.

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to Semaglutide will be initiated on a 0.25 mg dose (injection) once weekly for 4 weeks (first month) with an escalation to 0.5 mg for the second month, and 1.0 mg in the final month (three months total).

06

What researchers measure

Primary outcomes

  1. Percent weight change

    Percent weight change will be calculated. Negative values are indicative of weight loss. Positive values are indicative of weight gain.

    Time frame: Baseline, Week 12, 6-month follow-up

  2. Mean drinks per calendar day to assess alcohol use

    Mean drinks per calendar day will be assessed through timeline follow back interviews

    Time frame: Baseline, Week 4, Week 8, Week 12, 6-month follow-up

  3. Mean drinks per drinking day to assess Alcohol use

    Mean drinks per drinking day will be assessed through timeline follow back interviews

    Time frame: Baseline, Week 4, Week 8, Week 12, 6-month follow-up

  4. Mean number of heavy drinking days to assess Alcohol use

    Mean number of heavy drinking days will be assessed through timeline follow back interviews

    Time frame: Baseline, Week 4, Week 8, Week 12, 6-month follow-up

  5. Mean number of drinking vs abstinent days to assess Alcohol use

    Mean number of drinking vs abstinent days will be assessed through timeline follow back interviews

    Time frame: Baseline, Week 4, Week 8, Week 12, 6-month follow-up

07

Study locations

1 site
08

References and documents

Publications

  • Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, Tow AC, Dermody SS, Prince MA, Jordan R, McKee SA, Fletcher PJ, Claus ED, Klein KR. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025 Apr 1;82(4):395-405. doi: 10.1001/jamapsychiatry.2024.4789. PubMed 39937469 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.

Of 63 non-industry phase 1 interventional studies under Alcoholism, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 49. This study's planned 11 months is below that.

Counting every sponsor, half of 75 studies reached it within 28 months; a quarter within 19 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2025
First posted
Nov 3, 2025
StartActual
Mar 26, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223983
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Nov 3, 2025
Start date
Mar 26, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Valentina Ivezaj, PhD
principal investigator · Yale University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion